Trial · NCT03063450
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
NCT03063450, Phase 3, Completed, University of Southampton
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma. Trials, record NCT03063450. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03063450
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
- NCT number
- NCT03063450
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 332 participants, actual
- Lead sponsor
- University of Southampton
- Conditions
- Mesothelioma
- Interventions
- Nivolumab, Placebo
- First posted
- 2017-02-24
- Last updated
- 2025-04-10
- Other registries' IDs
- eudract:2016-003111-35
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival | Time from randomisation to date of death from any cause or time of censoring | Length of time participants are alive |
| Primary | Progression free survival | Time from randomisation to investigator-reported progression, death, or end of study (max. 12 months from last participant randomised) | Length of time participants are free of disease progression |
| Secondary | Overall response rate (modified RECIST or RECIST 1.1) | From randomisation and while on treatment | Response of disease to treatment |
| Secondary | EQ-5D-5L | At baseline, after cycles 3 and 6 (each cycle is 14 days) and 1, 6 and 12 months post progression/treatment discontinuation. | Quality of life |
| Secondary | CTCAE V4.03 | At baseline, after each treatment cycle (each cycle is 14 days) and each follow up visit. Up to 30 days post progression/treatment discontinuation. | Adverse events |
| Secondary | Health resource use | Up to max. 24 months. At baseline, after cycles 3 and 6 (each cycle is 14 days) and 1, 6 and 12 months post progression/treatment discontinuation. | Bespoke health resource use questionnaire capturing information on hospital visits. |
| Secondary | Progression-free survival (RECIST) | From randomisation until 28 days after completing treatment (max. 12 months), progression, or death | Time participant is free of disease progression, as measured by RECIST |
| Other | Translational | Samples collected at baseline and optional sample at progression (assessed up to 51 months from randomisation) | To correlate: 1. mutation burden with OS 2. immunosuppressive landscape (immune checkpoint expression and infiltration of immune cell) and nivolumab efficacy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03063450
GET https://conductscience.org/api/trials/v1/NCT03063450/registered